Related Experiment Videos

Effects of Atorvastatin on Th polarization in patients with acute myocardial infarction

Xiang Cheng1, Yu-Hua Liao, Jinying Zhang

  • 1The Laboratory of Cardiovascular Immunology, Institute of Cardiology, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.

European Journal of Heart Failure
|June 1, 2005
PubMed

Insights

Atorvastatin reduces T helper 1 cell development in acute myocardial infarction patients, potentially improving heart function. This study investigated atorvastatin

Area of Science:

  • Immunology
  • Cardiology
  • Pharmacology

Background:

  • Inflammation, regulated by T helper (Th) 1 and Th2 lymphocytes, influences heart failure post-acute myocardial infarction (AMI).
  • Statins are known to potentially improve cardiac function following AMI.

Purpose of the Study:

  • To investigate the impact of atorvastatin on T helper cell polarization in patients diagnosed with AMI.

Main Methods:

  • Peripheral blood mononuclear cells from AMI patients with and without atorvastatin treatment were analyzed.
  • Flow cytometry quantified cytokine-producing Th lymphocytes before and after in vitro atorvastatin exposure.

Main Results:

  • Atorvastatin treatment significantly decreased the ratio of IFN-gamma-producing T cells (Th1) in AMI patients.
  • In vitro atorvastatin exposure reduced Th1 development in the AMI-C group.
  • No significant changes were observed in interleukin-4-producing T cells (Th2) frequencies.

Conclusions:

  • Atorvastatin modulates Th1/Th2 polarization by reducing Th1 cell development without affecting Th2 cell function in AMI patients.
  • This regulation of T helper cell polarization may represent a mechanism by which atorvastatin enhances cardiac recovery after AMI.
Abstract

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...